MarcusOthoButlerMD

Oncology • Boston, MA

Medical Oncologist, Princess Margaret Cancer Centre Melanoma/Skin Oncology Site Lead Adoptive Cell Therapy, Tumor Immunotherapy Program

Join to view full profile

Dr. Butler is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Butler's full profile

Already have an account?

Office
44 Binney Street
Dana Farber Cancer Institute
Boston, MA 02115
Phone+1 617-632-2334

Fax+1 617-632-3479

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1996 - 2000
Johns Hopkins UniversityResidency, Internal Medicine, 1992 - 1995
Yale School of MedicineClass of 1992

Certifications & Licensure

MA State Medical License 1995 - 2012

Clinical Trials

Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma Start of enrollment: 2007 Aug 01
Completed
Phase 1
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Start of enrollment: 2016 Sep 01
Active, not recruiting
Phase 1
Roles: Contact, Principal Investigator
Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. Start of enrollment: 2022 May 02
Active, not recruiting
Phase 3
Roles: Contact, Principal Investigator
Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination Start of enrollment: 2015 Dec 01
Recruiting
Roles: Contact
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma Start of enrollment: 2023 Jul 03
Recruiting
Phase 2
Roles: Contact
Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL Start of enrollment: 2023 Jul 26
Recruiting
Phase 1
Roles: Principal Investigator, Contact
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Start of enrollment: 2023 Oct 31
Recruiting
Phase 2, Phase 3
Roles: Contact
Phase I Study of ANK-101 in Advanced Solid Tumors Start of enrollment: 2024 Jan 19
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Female Oncofertility and Immune Checkpoint Blockade in Melanoma: Where Are We Today?
Cha Len Lee, Erika Martinez, Diego Malon Gimenez, Thiago Pimentel Muniz, Marcus Otho Butler
Cancers. 2025-01-13
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors.
Florentia Dimitriou, Marlana M Orloff, Erica C Koch Hein, Phil F Cheng, Isaac F Hughes
European Journal of Cancer. 2025-01-01
3 citations
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238.
Jeffrey Weber, Michele Del Vecchio, Mario Mandalá, Helen Gogas, Ana M Arance
Journal of Clinical Oncology. 2024-11-01

Press Mentions

Accuracy of Skin Cancer Diagnosis Varies by Physician, Exam MethodNovember 14th, 2024
Medison Pharma Announces the Approvals by Health Canada and Therapeutics Goods Administration of KIMMTRAK® (Tebentafusp) for the Treatment of Unresectable or Metastatic Uveal MelanomaJune 8th, 2022
Asthma Society’s Pollen Tacker Predicts High Pollen Levels This WeekendJuly 14th, 2020
Join now to see all

Grant Support

Detection Of Immunogenic Ovarian Cancer AntigensNational Cancer Institute2000–2005